Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Recent Advances in SJS/TEN and RIME: Mechanisms, Treatments, and Guidelines
Description
The talk reviewed recent advances in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and reactive infectious mucocutaneous eruption (RIME), emphasizing that these are high-morbidity conditions with important acute and long-term psychological consequences. For SJS/TEN, the speaker highlighted common triggers from FAERS and pediatric reports, especially lamotrigine and other antiepileptics, plus important over-the-counter culprits such as ibuprofen and acetaminophen. New mechanistic studies suggest SJS/TEN pathogenesis is driven by multiple immune mediators, with cytotoxic T cells central, and pathways including granulysin, TNF, and emerging necroptosis signaling via RIPK1/3; timing of presentation may affect which mechanisms dominate. Landmark tissue studies using spatial proteomics, phospho-STAT staining, and single-cell transcriptomics identified interferon and TNF signatures and helped support JAK inhibition as a potential therapy. Clinically, about 15 published cases of JAK inhibitor use were discussed, but most involve adults or transplant/GVHD-like cases, with limited pediatric evidence and unclear benefit on re-epithelialization. A meta-analysis of 43 studies found the evidence base remains low power, with etanercept showing a mortality benefit versus supportive care, but comparisons across steroids, IVIG, cyclosporine, and other agents remain difficult. Because of limited data, consensus guidelines still drive care; they stress multidisciplinary management, biopsy from the edge of lesions, early ophthalmology and urology/gynecology consultation, wound care, and cautious, case-by-case systemic treatment decisions. For RIME, the speaker noted the shift from MIRM terminology, described an Australian case series dominated by Mycoplasma pneumoniae, and reviewed biopsy and cytokine data showing lymphocytic inflammation with some neutrophils and interferon/CXCL9-10/TNF signatures. Etanercept and steroids appear promising, but RIME research is hindered by lack of ICD-10 coding and standardized severity measures. Ongoing collaborative studies, registries, Delphi efforts, and randomized trials were presented as key next steps.
View moreConclusions
- Recent pediatric and mixed-age evidence suggests that SJS/TEN is driven by multiple overlapping immune pathways, with cytotoxic T cells, TNF, and type I/II interferon-JAK signaling all contributing to keratinocyte death.
- Drug causality remains important and is reinforced by FAERS data, with anti-epileptics, NSAIDs, acetaminophen, and antibiotics repeatedly emerging as common triggers in children.
- New spatial proteomics, immunohistochemistry, and single-cell transcriptomics point to interferon-JAK1 and TNF pathways as actionable biologic targets in SJS/TEN.
- JAK inhibitors appear promising for SJS/TEN based on small case reports and adult series, but pediatric evidence is essentially absent and robust comparative data are still lacking.
- Early etanercept may improve outcomes in SJS/TEN and RIME, but current evidence is mostly retrospective and heterogeneous, so definitive treatment recommendations remain uncertain.
- Meta-analytic evidence is weak because studies are small, diverse, and difficult to compare, though etanercept and cyclosporine show the most encouraging signals for mortality benefit.
- Consensus guidelines are increasingly detailed for supportive care and mucosal management, but systemic immunomodulatory therapy recommendations remain cautious because the evidence base is limited.
- Multidisciplinary care, including early ophthalmology, gynecology/urology, burn/wound care, and other subspecialties, is essential for improving acute management and reducing long-term sequelae.
- Psychological and quality-of-life consequences of SJS/TEN are substantial and likely under-addressed in pediatrics, indicating a need for structured follow-up and survivorship care.
- For RIME, biopsy and cytokine studies suggest it shares some inflammatory features with other mucocutaneous syndromes, including lymphocytes, neutrophils, CXCL9/10, TNF, and interferon dysregulation.
- RIME appears clinically heterogeneous and may be triggered by multiple infections, especially Mycoplasma pneumoniae, with disease severity and response varying by patient and treatment timing.
- Etanercept monotherapy may be effective in selected RIME cases and may shorten hospitalization, but the data remain limited to small case series.
- The field needs standardized diagnostic codes, validated activity/severity scores, and prospective multicenter registries to make treatment comparisons and trials more reliable.
- Future progress will depend on collaborative prospective studies and randomized trials to determine which immunomodulatory therapies truly improve outcomes in SJS/TEN and RIME.
- Pan S, Boisen J, Saad S. Idiopathic toxic epidermal necrolysis in a pediatric patient. Proc (Bayl Univ Med Cent). 2024 Feb 8;37(2):336-338. doi: 10.1080/08998280.2024.2301782. PMID: 38343491; PMCID: PMC10857542.#10.1080/08998280.2024.2301782
- Bayram-Ozgur et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis study from the FAERS database (2025).
- Stewart TJ, Farrell J, Frew JW. A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 2024 Sep;65(6):491-504.#10.1111/ajd.14329
- Nordmann TM et al. Spatial proteomics identifies JAKi as treatment for a lethal skin disease. Nature. 2024 Oct 16. doi: 10.1038/s41586-024-08061-0. Epub ahead of print. PMID: 39415009.#10.1038/s41586-024-08061-0
- Gibson A et al; AUS-SCAR Consortium; Peter JG; AFRiSCAR Consortium; Mallal SA, Phillips EJ. Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Commun. 2024 Oct 8;15(1):8722.#10.1038/s41467-024-52990-3
- Evidence for the Use of Janus Kinase (JAK) Inhibitors in the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Scoping Review. Australas J Dermatol.#10.1111/ajd.70017
- Systemic immunomodulating therapies for epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta-analysis.#10.3410/f.727449569.793533517
- S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) – Part 1: Diagnosis, initial management, and immunomodulating systemic therapy.#10.32388/53yqte
- Ryder CY, Pedersen EA, Mancuso JB. Reactive infectious mucocutaneous eruption secondary to SARS-CoV-2. JAAD Case Rep. 2021 Dec;18:103-105. doi: 10.1016/j.jdcr.2021.10.007. Epub 2021 Oct 20.#10.1016/j.jdcr.2021.10.007
- Mycoplasma pneumoniae-Induced Rash and Mucositis: Clinicopathologic Characterization of 11 Cases. Journal of Cutaneous Pathology.#10.1016/j.idcr.2024.e01973
- Lang Houser et al. Journal of Cutaneous Pathology article on Mycoplasma-RIME biopsy findings.
- Roberts, Melchiorre, Saldanha, Shaffii, and Boyle. Toxic epidermal necrolysis-like lupus. Clinical and Experimental Dermatology.
- Tan et al. Dual dysregulation of TNF/interferon signaling and classical monocytes are implicated in Reactive Infectious Mucocutaneous Eruptions. JCI Insight. 2025 Nov 20:e194642.#10.1172/jci.insight.194642
- Miller MM, Kamath S, Hughes M, Harter N, Luu M. Evaluation of Etanercept for Treatment of Reactive Infectious Mucocutaneous Eruption. JAMA Dermatol. 2021;157(2):230-232. doi:10.1001/jamadermatol.2020.5166.#10.1001/jamadermatol.2020.5166
- Jobe A, Elkhammas H, Oldenburg R, Luu M, Zilberstein A, Ramien M, Chiu Y. Etanercept Monotherapy in Reactive Infectious Mucocutaneous Eruption - A Case Series. (unpublished data).#10.1016/s0022-202x(26)00569-5